70904-65-3

Upstream product

• 1210-96-4 1,3-dimethoxy-4,6-dinitrobenzene 
• 7647-01-0 hydrogenchloride 
• 327-92-4 1,5-difluoro-2,4-dinitrobenzene 
• 3698-83-7 2,4-dichloro-1,5-dinitrobenzene 

Downstream Products

• 176915-40-5 2-(2,4-Dimethoxy-5-nitro-phenylamino)-benzoic acid 
• 176915-41-6 2-(2,4-Dimethoxy-5-nitro-phenylamino)-N-(3-dimethylamino-propyl)-benzamide 
• 1112984-82-3 C₃₄H₅₁N₃O₈ 
• 1454693-39-0 C₃₃H₄₉N₃O₈ 
• 1342299-60-8 C₁₆H₂₄N₂O₅ 
• 1342299-62-0 C₃₉H₅₇N₃O₈ 
• 1178882-11-5 C₆₈H₉₂N₆O₃₀ 
• 857950-16-4 2,4-dimethoxy-5-nitroacetanilide 
• 1619224-27-9 C₅₆H₈₆N₄O₁₂ 

Relevant academic research and scientific papers

2,4-dibasic miazines compound

The invention belongs to the field of medical chemistry, relates to a 2,4-dibasic miazines compound and specifically relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof, a drug compound thereof and an application thereof in treating EGFR or/and ALK mediated diseases.

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula (I), wherein the variables are as defined herein.

Synthesis of crescent aromatic oligoamides

This article describes the synthetic procedures for the preparation of crescent (and helical) aromatic oligoamides developed in recent years in our laboratory. The large-scale preparation of a variety of monomers derived from various tetrasubstituted benzenes is presented. Three different strategies for constructing various oligomers consisting of meta- and meta/para-linked benzene residues are discussed. Factors affecting coupling efficiency and yields are analyzed. The developed synthetic methods have provided the basis for the preparation of longer oligomers and for the development of solid-phase synthesis.

Positive allosteric modulators of the nicotinic acetylcholine receptor

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.

Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis- bioreductive agent nitracrine N-oxide

A series of nuclear-substituted derivatives of nitracrine N-oxide (2; a bis-bioreductive hypoxia-selective cytotoxin) were prepared and evaluated, seeking analogues of lower nitroacridine reduction potential. Disubstitution with Me or OMe groups at the 4-